Outside U.S. — Revenue

Geographic · Revenue

Eli Lilly Outside U.S. — Revenue increased by 1.8% to $6.41B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 42.5%, from $4.50B to $6.41B. Over 4 years (FY 2021 to FY 2025), Outside U.S. — Revenue shows an upward trend with a 17.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2017
Last reportedQ4 2025
Rolls up toTotal Revenue

How to read this metric

An increase indicates successful market penetration or growth in international regions, while a decrease may signal competitive pressure, unfavorable currency fluctuations, or regulatory challenges in foreign markets.

Detailed definition

This metric represents the total net sales generated from pharmaceutical products sold in markets outside of the United...

Peer comparison

Peer pharmaceutical companies typically report international revenue as a distinct geographic segment, allowing for comparison of global market share and exposure to ex-US pricing pressures.

Metric ID: lly_segment_non_us_revenues

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$3.04B$2.78B$2.82B$2.64B$2.55B$2.52B$2.64B$2.52B$2.78B$4.13B$2.90B$3.07B$3.47B$3.63B$4.50B$4.24B$4.74B$6.30B$6.41B
QoQ Change-8.3%+1.5%-6.7%-3.1%-1.3%+4.9%-4.5%+10.2%+48.5%-29.8%+6.1%+12.8%+4.6%+24.1%-5.8%+11.9%+32.8%+1.8%
YoY Change-15.9%-9.5%-6.4%-4.2%+8.9%+63.9%+9.6%+21.8%+24.7%-12.2%+55.3%+37.9%+36.8%+73.8%+42.5%
Range$2.52B$6.41B
CAGR+18.1%
Avg YoY Growth+21.8%
Median YoY Growth+21.8%
Current Streak3 quarters growth

Frequently Asked Questions

What is Eli Lilly's outside u.s. — revenue?
Eli Lilly (LLY) reported outside u.s. — revenue of $6.41B in Q4 2025.
How has Eli Lilly's outside u.s. — revenue changed year-over-year?
Eli Lilly's outside u.s. — revenue increased by 42.5% year-over-year, from $4.50B to $6.41B.
What is the long-term trend for Eli Lilly's outside u.s. — revenue?
Over 4 years (2021 to 2025), Eli Lilly's outside u.s. — revenue has grown at a 17.2% compound annual growth rate (CAGR), from $11.51B to $21.70B.
What does outside u.s. — revenue mean?
The total revenue generated from sales of pharmaceutical products in all countries outside of the United States.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.